Coriolis Pharma Appoints Silvia Steyrer-Gruber as New Chief Executive Officer

The Appointment Marks a Next Step in the Organic Growth Journey of Coriolis Pharma

MARTINSRIED-MUNICH, Germany, May 04, 2022 / B3C newswire / -- Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, today announced that Silvia Steyrer-Gruber has been named as Chief Executive Officer.

Silvia brings strong international leadership experience to Coriolis. In her previous role as Managing Director Europe at Exeltis (part of the Insud Pharma Group), she was responsible for the European branded pharmaceutical business of the family-owned Spanish Multinational Healthcare Group. Prior to that, Silvia served at Baxter, Kwizda Pharma and Serono in senior roles, and gained more than 25 years of experience in Biotech, Vaccine and Pharmaceutical companies.

Silvia said “it is a highly exciting time to join the great team at Coriolis Pharma, as the company is set to further expedite its growth and internationalization over the next years. By innovating formulation for its clients, Coriolis Pharma contributes to bringing new therapeutics to patients, many of them in areas of high unmet medical need. I was attracted by the strong focus on scientific innovation, coupled with a very high client orientation and, not last, the wish to even further shape an outstanding place to work for the own Coriolis team.”

Dr. Michael Wiggenhorn and Thomas Wiggenhorn co-founded Coriolis Pharma in 2008 in order to develop a leading specialty service provider in the area of formulation innovation and have grown the company to its current strong position. Michael and Thomas will now step up to the Board of Directors, also focusing on strategic projects for the further growth of Coriolis Pharma.

“The appointment of Silvia marks the next step in our growth journey for Coriolis Pharma,” said Thomas Wiggenhorn. “Under her leadership, the management team of Coriolis will now develop the future growth concept for geographical expansion as well as the expansion of our service offerings.”

“Our scientific expertise will remain the cornerstone of our client collaboration for the future,” said Dr. Michael Wiggenhorn. “The recent announcements of new members for the Scientific Advisory Board as well as the partnership with U-Medico in Japan emphasize this strongly.”

Silvia will continue to work in close collaboration with Michael and Thomas.

Caption: Silvia Steyrer-Gruber, CEO of Coriolis Pharma

For high resolution please click the image.

About Coriolis Pharma
Coriolis Pharma is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs and vaccines.
The motivation of the team is to enable the development of innovative drugs by performing outstanding biopharmaceutical research to improve the quality of life for humankind.
The vision of Coriolis Pharma is to revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products. Coriolis Pharma thereby enables future therapies to be made available to humankind efficiently and on time.
As a people and team-oriented company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, Coriolis Pharma provides cutting-edge services and tailor-made solutions for their clients.
Coriolis company culture is based on diversity, teamwork, and open and appreciative communication. That's why wonderful people from over 25 nations around the world work together successfully at Coriolis.

Contact

Coriolis Pharma Research GmbH
Dr. Daniel Weinbuch
Scientific Marketing Specialist
+49 (0) 89 4177 60 – 149
daniel.weinbuch@coriolis-pharma.com
Fraunhoferstr. 18b
82152 Martinsried-Munich
Germany
www.coriolis-pharma.com

Keywords: Laboratories; Research; Drug Delivery Systems;  Drug Compounding; Biophysical Phenomena; Biological Products; Drug Therapy; Pharmaceutical Preparations; Germany

Published by B3C newswire